LOC284009 Inhibitors
LOC284009 inhibitors Sorafenib and Sunitinib are tyrosine kinase inhibitors that can disrupt downstream signaling pathways that may involve LOC284009. Erlotinib and ZD6474, which target EGFR, along with PD173074, which targets FGFR, may alter the phosphorylation state of proteins and can influence LOC284009 if it is a part of these signaling cascades. Dasatinib disrupts SRC-family kinase-mediated signaling, which could change the function of LOC284009 if it is associated with this pathway.
LY294002 and U0126 are inhibitors of the PI3K/Akt and MAPK/ERK pathways, respectively, which are critical for cell proliferation and survival, and their inhibition may affect LOC284009's activity in these pathways. SP600125 and SB203580 are inhibitors of the JNK and p38 MAPK pathways, respectively, and their inhibition can modulate the function of LOC284009 if it is a component of these signaling pathways. Y-27632 is a ROCK inhibitor that may alter cytoskeletal dynamics and related signaling, which could influence LOC284009 if it is part of the Rho/ROCK pathway. Lastly, MG132 interferes with proteasomal degradation, potentially leading to altered levels of LOC284009 if it is typically regulated through ubiquitination-mediated degradation.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Inhibits multiple tyrosine kinases involved in tumor growth and angiogenesis, potentially altering LOC284009 activity if related. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Inhibits vascular endothelial growth factor receptors, possibly affecting LOC284009 if it is involved in angiogenic signaling. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Targets the epidermal growth factor receptor, potentially influencing LOC284009 if it interacts with this receptor's signaling. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Inhibits VEGFR and EGFR signaling, potentially downregulating LOC284009 if it is implicated in these pathways. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
Targets fibroblast growth factor receptors, possibly altering LOC284009 activity if it is part of FGF signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
SRC-family kinase inhibitor, may change LOC284009 function if it is associated with SRC kinase-mediated signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K, potentially affecting LOC284009 if it is regulated by the PI3K/Akt pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, may modulate LOC284009 if it operates within or is regulated by the JNK signaling pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAPK, potentially affecting LOC284009 if it relies on p38 MAPK pathway signaling. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
ROCK inhibitor, may alter LOC284009 function if it is implicated in Rho/ROCK pathway signaling. | ||||||